PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Infect Dis. Author manuscript; available in PMC Feb 1, 2011.
Published in final edited form as:
PMCID: PMC2805776
NIHMSID: NIHMS158833
Elevations in mortality due to weaning persist into the second year of life among uninfected children born to HIV-infected mothers
Louise Kuhn,1 Moses Sinkala,2 Katherine Semrau,3 Chipepo Kankasa,4 Prisca Kasonde,4 Mwiya Mwiya,4 Chih-Chi Hu,5 Wei-Yann Tsai,5 Donald M. Thea,3 and Grace M. Aldrovandi6
1Gertrude H. Sergievsky Center, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
2Lusaka District Health Management Team, Lusaka, Zambia
3Center for International Health & Development, Boston University School of Public Health, Boston, MA
4University Teaching Hospital, University of Zambia, Lusaka, Zambia
5Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY
6Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA
Address for correspondence: Dr. Louise Kuhn, Sergievsky Center, Columbia University, 630 W 168th Street, New York, NY 10032. Tel 212-305-2398. Fax: 212-305-2426. lk24/at/columbia.edu
Background
Early weaning has been recommended to reduce postnatal HIV transmission. We evaluated the safety of stopping breastfeeding at different ages for mortality of uninfected children born to HIV-infected mothers.
Methods
During a trial of early weaning, 958 HIV-infected mothers and their infants were recruited and followed from birth to 24 months in Lusaka, Zambia. Half of the cohort was randomized to wean abruptly at 4 months and the other half to continue breastfeeding. We examined associations between uninfected child mortality and actual breastfeeding duration investigating possible confounding and effect modification.
Results
The mortality rate among 749 uninfected children was 9.4% by 12 months and 13.6% by 24 months. Weaning during the interval encouraged by the protocol (4-5 months) was associated with a 2.03-fold increased risk of mortality (95% CI: 1.13 - 3.65), weaning 6-11 months a 3.54-fold increase (95% CI: 1.68 - 7.46) and 12-18 months a 4.22-fold increase (95% CI: 1.59 - 11.24). Significant effect modification was detected such that risks associated with weaning were stronger among infants born to mothers with higher CD4 counts (>350 cells/mL).
Conclusion
Shortening the normal duration of breastfeeding for uninfected children born to HIV-infected mothers living in low resource settings is associated with significant increases mortality extending into the second year of life. Intensive nutritional and counseling interventions reduce, but do not eliminate, this excess mortality.
Summary
Shortening breastfeeding duration to less than 18 months was associated with significant increases in mortality among uninfected children born to HIV-infected mothers in Lusaka, Zambia. Nutritional and counseling interventions did not eliminate excess mortality associated with weaning.
HIV transmission continues to occur throughout the duration of breastfeeding prompting many advocates of prevention of mother-to-child HIV transmission programs to recommend early weaning for infants born to HIV-infected mothers [1-4]. However, benefits of breastfeeding for survival and well-being of infants and young children are well established [5,6] creating a tragic impasse for the communities, primarily in sub-Saharan Africa, most severely affected by the HIV/AIDS pandemic.
We hypothesized that early weaning at 4 months of age could be made safe enough to justify recommending this practice to prevent HIV transmission and conducted a trial to test this hypothesis in Lusaka, Zambia. Because benefits of breastfeeding are thought to decline as children age [7], we hypothesized that by 4 months children would have passed the critical developmental age when breastfeeding is essential to their survival. We also provided a fortified weaning cereal that needed cooking in order to minimize risks associated with preparing infant formula with contaminated water. The cereal contained all the macro- and micro-nutrient requirements of 4-6 month old infants. Cotrimoxazole was given to all infants as well as intensive counseling and education for mothers.
We have reported that the trial found no benefit of early weaning for HIV-free survival [8]. Here we investigate the effects of weaning at different ages on mortality of uninfected children born to HIV-infected mothers. Specifically, we were interested in whether we could determine a safe age when weaning could be recommended.
Study design
We recruited a cohort of 958 HIV-infected mothers into a randomized trial of early weaning in Lusaka, Zambia. All women planned to breastfeed to at least 4 months and were counseled to breastfeed exclusively [9]. Half of the cohort was encouraged to abruptly wean at 4 months and the other half was encouraged to continue breastfeeding and to wean at a time of their own choosing. Here we examine whether the actual age of the child when all breastfeeding ended i.e. weaning age, was associated with mortality through 24 months among uninfected children.
Study procedures
HIV-infected pregnant women were recruited between May 2001 and September 2004 from two antenatal clinics in Lusaka, Zambia that offered voluntary HIV counseling and testing and single-dose nevirapine prophylaxis. All women signed informed consent. The study was approved by Human Subjects Committees at the investigators’ institutions.
Blood was drawn from women at enrollment and two subsequent antenatal visits were scheduled for counseling prior to delivery. Sociodemographic and clinical history were collected at enrollment and obstetric/neonatal data after delivery. Infant heelstick blood samples were collected onto filter paper on the day of birth, at 1 week, and at 1, 2, 3, 4, 4 ½, 5, 6, 9, 12, 15, 18, 21, and 24 months of age. Clinic visits were scheduled at these same time-points and detailed questions were asked about infant feeding practices by separate study staff than those performing the counseling. Home visits were scheduled at 4 days and then again at time-points interspersed between clinic visits so that contact occurred every 2 weeks through 5 months. All randomized infants were followed on this schedule to 24 months. Home visit teams tracked participants who did not return for appointments. Information about all child deaths was sought from hospital and clinic records as well as interviews with caretakers and health care personnel. The circumstances of all deaths were reviewed and verbal autopsies conducted to identify causes of death.
Antiretroviral drugs were not available in the public sector during most of the study period but became available after May 2004 [10]. Women eligible for treatment based on Zambian guidelines were started on first-line regimens if they consented to treatment. Cotrimoxazole was given to all women with CD4 counts <200 after November 2003 [11]. Cotrimoxazole was given to all infants between 6 weeks and 12 months. Growth monitoring was done at least monthly, the under-five immunizations were given according to the national guidelines and children from either group with evidence of failure to thrive were provided with nutrition supplements. Children in the intervention group were provided with a 3-month supply of commercial infant formula (not pre-mixed) and a fortified weaning cereal regardless of growth status from 4 months of age. The cereal was maize meal-based fortified with milk powder, sugar, oil and micronutrients.
Laboratory methods
Maternal blood collected at enrollment was tested for CD4 and CD8 counts (FACSCount, BD Immunocytometry Systems, San Jose, CA), hemoglobin (Hemocue® system, Lake Forest, CA) and plasma viral load (Roche Amplicor® 1.5, Roche, Branchburg, NJ). Maternal CD4 counts were repeated 12 months after delivery. Infant heelstick samples were tested for HIV-1 DNA by realtime PCR at the end of the study. All positives were confirmed on at least two samples if available, and, if not, the same sample was re-tested to confirm. Amplification of the beta-globin gene was performed in all samples to ensure adequate cell numbers thereby minimizing false negative results due to inadequate sample.
Statistical methods
Children were considered uninfected if their last available PCR test was negative. Three children who died without a prior PCR test were excluded. Uninfected child mortality through 24 months of age was analyzed using Cox Proportional Hazards models. Children were included in the analysis up to the time of their last negative test or until their death (if they died without ever testing positive). Breastfeeding cessation (weaning) was treated as a time-dependent variable. The age of weaning was calculated based on the exact age that all breastfeeding stopped. The maternal report provided at the clinic visit soonest after weaning was used. Children who died were assumed to have been breastfed up to their date of death unless study records specifically reported that breastfeeding ceased prior to the start of the illness immediately preceding the child's death. Curves to display survival probabilities by different weaning ages utilizing the time-dependent covariate for weaning were generated utilizing Cox models. Piecewise time-dependent covariates for weaning age were introduced to examine whether the effects of weaning on mortality were constant across child age. Confounding was investigated by examining whether the inclusion of each putative confounder changed the magnitude of the weaning association by more than 10%. Any factor that modified the primary relationship in this way, or which was significantly associated with mortality was included in the final model. Effect modification was investigated through stratification and multiplicative interaction terms in the Cox model. To compare characteristics between groups, differences in categorical parameters were tested using chi-squared tests, normally-distributed continuous variables using t-tests, and non-normal continuous variables using Wilcoxon rank sum tests. Analyses were done using SAS (Cary, NC).
Mortality rates
Of 958 mother-child pairs randomized in the study, 749 had a last PCR test which was negative. The mortality rate among uninfected children was 2.8% (21 deaths) by 4 months, 9.4% (65 deaths) by 12 months and 13.6% (91 deaths) by 24 months. The median time between the last negative result and death was 31 days (inter-quartile range [IQR] 16 - 53). The early mortality rate in the randomized cohort is an under-estimate because the study aimed only to randomize mother-child pairs surviving to one month of age. In order to generate estimates of under two year mortality that do not under-represent neonatal mortality, we examined neonatal mortality in the larger cohort of 1002 live-births, including those excluded prior to randomization and censoring those who tested HIV positive before 28 days. In this birth cohort, neonatal mortality was 4.4%.
Maternal, household and infant characteristics of the surviving and deceased uninfected children are displayed in Table 1. Children who died were more likely to have mothers with low CD4 counts and high viral loads, were more likely to have had mothers who died, to have lived in households reporting food insecurity and with more than one child under 5 years of age, to have been of low birth weight and to have weaned earlier.
Table 1
Table 1
Maternal, household and infant characteristics of 749 uninfected children born to HIV-infected mothers, Lusaka, Zambia
Diarrhea was the leading cause of death contributing to 61.5% of deaths 6-24 months but was not a major cause of mortality for those under 6 months of age. Pneumonia was the second major cause of death contributing to deaths across all age categories (42.9% of deaths overall). If sepsis and pneumonia are combined into one category, they became the leading cause of death contributing to 84.6% of deaths under 6 months and to 41.5% of deaths 6-24 months (Table 2).
Table 2
Table 2
Causes of death among 91 uninfected children born to HIV-infected mothers
Weaning and mortality
Weaning was associated with a more than 2-fold increase (Hazard Ratio [HR]=2.56 95% CI: 1.53-4.28) in mortality over the full period from birth to 24 months. Under two-year mortality in the cohort of children who did not stop breastfeeding before 18 months was 9.7% and was 17.4% in the cohort who stopped breastfeeding at 5 months (Figure 1).
Figure 1
Figure 1
Survival function estimates calculated from a Cox Proportional Hazards model utilizing breastfeeding cessation as a time-dependent covariate for uninfected children born to HIV-infected mothers if weaned at 5 months of age (dashed line) or if weaned at (more ...)
To investigate if weaning became safer as children became older, we examined the effects of weaning before 4 months, 4-5 months, 6-11 months and 12-18 months utilizing four time-dependent covariates for these periods with those who weaned at ages older than 18 months as the comparison. Elevated risks of uninfected child mortality persisted through 18 months. Weaning at 4-5 months, the period encouraged in the intervention group and especially supported with additional nutritional interventions, was associated with a significant 2.03-fold elevation in mortality (95% CI: 1.13 - 3.65), albeit slightly lower than observed in other intervals. Weaning 6-11 months was associated with a 3.54-fold increase (95% CI: 1.68 - 7.46) and weaning 12-18 months a 4.22-fold increase (95% CI: 1.59 - 11.24) in uninfected child mortality compared to those weaning at ages older than 18 months (Table 3). The adverse effects of weaning were not confined to the period immediately after breastfeeding ended. Among children who stopped breastfeeding at 4 months, the absence of breast milk was associated with significantly increased mortality in the period 2 months after weaning (RH=2.17 95% CI: 1.13-4.16). In the acute period (within the first 2 months after weaning), weaning-related mortality was not as elevated (RH=1.61 95% CI: 0.48-5.42).
Table 3
Table 3
Magnitude of the elevation in uninfected child death associated with early weaning at different ages relative to weaning at ages older than 18 months.
Confounders and effect modifiers
We investigated if any other factors either alone or together confounded the relationship between weaning and mortality. Low maternal CD4 count during pregnancy, maternal mortality, low birth weight, having more than one other child in the household less than 5 years old and reported food insecurity were each independently associated with significantly increased uninfected child mortality in multivariate analysis but did not account for the relationship between weaning and mortality. After adjustment for these factors, the absence of breastfeeding continued to be associated with significantly increased risk of uninfected child mortality (Table 4). Weaning was associated with significantly increased risk of mortality in both the intervention group (RH=3.19 95% CI: 1.15-8.83) and the control group (RH=2.84 95% CI: 1.38-5.83) after adjusting for these same factors.
Table 4
Table 4
Factors associated with under 2-year mortality among uninfected children born to HIV-infected mothers
Maternal CD4 count measured during pregnancy was a significant effect modifier of the relationship between weaning and mortality. When maternal CD4 counts were high (>350 cells/ml), weaning was associated with a more than 4-fold increased risk of death (HR= 4.16 95% CI: 1.90 – 9.13) after adjusting for other confounders (Table 4). The weaning-mortality association was attenuated when maternal CD4 counts were low. Correspondingly, the association between low maternal CD4 counts and increased uninfected child mortality was strongest among breastfed infants (Figure 2, Table 4). Taking into account this interaction, as well as adjusting for maternal mortality, birth weight, other children in the household and food insecurity, the relative hazard of death associated with weaning before 6 months was 3.64 (95% CI: 1.63-8.14), weaning 6-11 months 7.63 (95% CI: 2.84-20.45), and weaning 12-18 months 8.96 (95% CI: 2.94-27.29).
Figure 2
Figure 2
Survival function estimates calculated from a Cox Proportional Hazards model using breastfeeding cessation as a time-dependent covariate for uninfected children born to HIV-infected mothers if weaned at 5 months of age (dashed line) or if weaned at 18 (more ...)
There was no evidence that markers of more beneficial socioeconomic position (including availability of electricity, domestic water source, maternal education, cooking facilities etc.) modified the association between weaning and mortality. None of the interaction terms was close to statistical significance. Further adjustment for maternal initiation of antiretroviral therapy or for the era when antiretroviral therapy became available had no appreciable effect on the results.
Premature truncation of the usual breastfeeding duration more than doubled the risk of death among uninfected children and the increase was more than 4-fold if mothers were not yet immunocompromised. Weaning at older ages continued to confer elevated mortality risks with 3- and 4-fold elevations with weaning between 6-11 months and 12-18 months, respectively, relative to breastfeeding for longer than 18 months. Mortality elevations were > 7-fold higher with weaning 6-11 months and 12-18 months if mothers had CD4 counts >350 cells/uL. These sobering results are consistent with prior studies which have observed among the general population that breastfeeding continues to protect against mortality even into the second year of life [5,7,12].
There was some evidence that the study interventions to support early weaning were beneficial. These interventions included counseling, education about preparation of replacement feeds and hygiene, growth monitoring, including nutritional supplementation of children manifesting signs of failure to thrive, cotrimoxazole, and provision of a 3-month supply of nutritionally-replete replacement foods. Hazard ratios associated with weaning during the study-supported interval of 4-5 months were slightly lower than elevations observed at older ages. Despite these interventions, weaning was associated with a more than 2-fold higher risk of death than continued breastfeeding. It is unclear what more could be added to make weaning safer than what was done as part of our study. It is possible that we have reached a biological threshold. Moreover, adverse effects of early weaning were not confined to the acute period immediately after weaning, suggesting that it is the absence of breast milk, rather than some temporary difficulty of the child adjusting to change, that is responsible for elevated mortality. It is likely that death due to weaning will be greater in real-world program situations where the extent of education and nutritional support is less than provided by our trial. Higher mortality rates have been observed in program settings [13].
We did not observe attenuation of the hazard ratios associated with weaning among women with more advantaged socioeconomic characteristics but numbers of women who met even crude indicators of advantage were small. Benefits of breastfeeding are demonstrated even in well-resourced settings e.g. in the United Kingdom, where breastfeeding was found to be associated with significantly reduced risks of severe diarrhea and pneumonia-related morbidity resulting in hospitalization [14]. Our hazard ratios may be biased towards the null by the nature of clinical research which over-represents motivated and compliant participants and provides a health service safety net with easier access to medical care and medications.
It is intriguing that the benefits of breastfeeding were greatest among women with higher CD4 counts. Although some risks associated with weaning may be in part related to environmental factors, the effect modification by maternal immune status highlights the importance of immunologically-active components of breast milk [15,16]. Our findings suggest that there may be some deficiencies in breast milk of immunocompromised women but these are yet to be identified [17].
Our results pertaining to the effects of early weaning on uninfected child mortality should be viewed in the context of HIV-free survival. The only reason to encourage early weaning is to reduce HIV transmission. Guidelines for uninfected women are unambiguous in their support for breastfeeding to 24 months or longer.[18] Our study was conducted largely prior to the availability of antiretroviral therapy for women. We have previously reported in both intent-to-treat analysis[8] and in analyses based on actual behavior[19] that early weaning resulted in no net benefit for HIV-free survival. Benefits for HIV reduction were off-set by elevations in uninfected child mortality. There are encouraging new data that antiretroviral drug regimens given as prophylaxis to the infant can reduce post-natal HIV transmission [20,21]. Mothers receiving effective antiretroviral therapeutic regimens also appear to be at low risk of HIV transmission [22,23]. When antiretroviral drugs are given, the risks for uninfected child mortality take on greater salience as even small elevations can counter-balance the now lessened HIV transmission risks. The balance also shifts among women who are at low risk of transmitting such as women with high CD4 counts. As we demonstrate here, women least likely to transmit HIV because of higher CD4 counts are also those for whom stopping breastfeeding confers the greatest dangers. As we have previously reported, even in the absence of antiretroviral therapy in women with higher CD4 counts, there is net benefit in terms of HIV-free survival with longer breastfeeding [19].
There are limitations of our analysis. We aimed to reduce the risks of reverse causality by reviewing the clinical circumstances of each death to exclude deaths where underlying illness was the motivation for weaning but we acknowledge that we may not have had all necessary information in every case. Our observation that early weaning was associated with death in both the intervention and the control group, despite the vastly different reasons for early weaning in these two groups, strengthens our inference about the effects of early weaning on mortality. We also investigated possible confounding by several socioeconomic and clinical factors known to be associated infant and young child death and none of these factors accounted for the associations. Unmeasured confounders may play a role but, given the consistency of our results with biological plausibility and studies in uninfected populations, this is unlikely. One of the greatest strengths of our cohort is the degree of heterogeneity of feeding practice. Other studies among HIV-infected women tend to be more homogenous in their feeding practices limiting the comparisons possible. The fact that women in the intervention group were specifically encouraged to wean early also minimizes the usual reasons for early weaning making our associations less prone to the confounding factors that may dominate in other studies precluding sufficient variability for adequate statistical adjustment.
Support is needed for programs in low resource settings to incorporate antiretroviral therapy for pregnant women with low CD4 counts and other strategies addressing HIV transmission over the postnatal period so that breastfeeding for a normal duration can be unambiguously supported. Our data, consistent with prior data among uninfected children, demonstrate that survival of uninfected children born to HIV-infected mothers is compromised through the second year of life when breastfeeding is stopped early. Nutrition, education and counseling interventions may reduce, but do not eliminate, this excess mortality.
Acknowledgements
We would like to thank the Zambian families who participated in the research and all the study staff and volunteers. We gratefully acknowledge assistance with aspects of the design and conduct of the study from: Drs. Marc Bulterys, Elwyn Chomba, Lynne Mofenson, Ellen Piwoz, Kevin Ryan, Nancy Scott, Cheswa Vwalika, Jan Walter.
The study was supported by grants from the National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) (R01 HD 39611 and R01 HD 40777). GMA is a recipient of the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) Scientist Award. None of the authors has any conflicts of interest to declare.
1. Ekpini ER, Wiktor SZ, Satten GA, et al. Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire. Lancet. 1997;349:1054–9. [PubMed]
2. Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breast feeding: a study in Malawi. JAMA. 1999;282:744–9. [PubMed]
3. Fawzi W, Msamanga G, Spiegelman D, et al. Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2002 Nov 1;31:331–8. [PubMed]
4. Breastfeeding and HIV International Transmission Study Group Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis. 2004 Jun 15;189:2154–66. [PubMed]
5. Taha TE, Kumwenda NI, Hoover DR, et al. The impact of breastfeeding on the health of HIV-positive mothers and their children in sub-Saharan Africa. Bull WHO. 2006 Jul;84:546–54. [PubMed]
6. Bahl R, Frost C, Kirkwood BR, et al. Infant feeding patterns and risks of death and hospitalization in the first half of infancy: multicentre cohort study. Bull WHO. 2005;83:418–26. [PubMed]
7. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet. 2000 Feb 5;355:451–5. [PubMed]
8. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt cessation of breastfeeding on HIV-free survival of children in Zambia. N Engl J Med. 2008;359:130–41. [PMC free article] [PubMed]
9. Kuhn L, Sinkala M, Kankasa C, et al. High Uptake of Exclusive Breastfeeding and Reduced Early Post-natal HIV Transmission. PLOS ONE. 2007;2(12):e1363. doi:10.1371/journal.pone.0001363. [PMC free article] [PubMed]
10. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006 Aug 16;296:782–93. [PubMed]
11. Walter J, Mwiya M, Scott N, et al. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts. J Infect Dis. 2006 Dec 1;194:1510–8. [PMC free article] [PubMed]
12. Lawrence R, Lawrence R. Breastfeeding: A guide for the medical professional. Mosby, Inc.; St Louis, Missouri: 1999.
13. Kagaayi J, Gray RH, Brahmbhatt H, et al. Survival of infants born to HIV-positive mothers by feeding modality in Rakai, Uganda. PLOS ONE. 2008;3:e3877. doi:10.1371/journal.pone.0003877. [PMC free article] [PubMed]
14. Quigley MA, Kelly YJ, Sacker A. Breastfeeding and hospitalization for diarrheal and respiratory infection in the United Kingdom Millennium Cohort Study. Pediatrics. 2007;119:e837–e842. [PubMed]
15. Goldman AS. The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J. 1993;12:664–71. [PubMed]
16. Labbok MH, Clark D, Goldman AS. Breastfeeding: maintaining an irreplaceable immunological resource. Nature Reviews. 2004 Jul;4:565–72. Immunology. [PubMed]
17. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast-feeding HIV-infected and HIV-uninfected women in Botswana. J Infect Dis. 2007;196:562–5. [PubMed]
18. World Health Organization Planning guide for national implementation of the global strategy for infant and young child feeding. 2006. http://www who int/nutrition/publications/Planning_guide pdf.
19. Kuhn L, Aldrovandi GM, Sinkala M, et al. Differential effects of early weaning for HIV-free survival of children born to HIV-infected mothers by severity of maternal disease. PLOS ONE. 2009;4:e6059. doi:10.1371/journal.pone.0006059. [PMC free article] [PubMed]
20. Six Week Extended-Dose Nevirapine (SWEN) Study Team Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008;372:300–13. [PubMed]
21. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008;359:119–29. [PubMed]
22. Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLOS Medicine. 2007 Aug 21;4:e257. [PMC free article] [PubMed]
23. Palombi L, Marazzi MC, Voetberg A, Magid MA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS. 2007;21(Suppl 4):S 65–S 71. [PubMed]